A M M Haydon1, R J Macinnis, D R English, H Morris, G G Giles. 1. Department of Epidemiology and Preventive Medicine, Monash Medical School, Alfred Hospital, Melbourne 3004, Australia. andrew.haydon@med.monash.edu.au
Abstract
BACKGROUND: Recent reports have shown that physical activity improves the outcome of patients with colorectal cancer as well as breast and prostate cancer. However, the mechanisms whereby physical activity reduces cancer mortality are not well established. METHODS: Incident cases of colorectal cancer were identified among participants of the Melbourne Collaborative Cohort Study, a prospective cohort study of 41,528 Australians recruited from 1990 to 1994. Information on tumour site and stage, treatments given, recurrences, and deaths were obtained from systematic review of the medical records. Baseline assessments of physical activity and body size were made, and cases with available plasma had pre-diagnosis insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) levels measured. We assessed associations between these hormones and colorectal cancer specific deaths with respect to physical activity. RESULTS: A total of 526 cases of colorectal cancer were identified, of which 443 had IGF-1/IGFBP-3 levels measured. Median follow up among survivors was 5.6 years. For the physically active, increasing IGFBP-3 by 26.2 nmol/l was associated with a 48% reduction in colorectal cancer specific deaths (adjusted hazard ratio (HR) 0.52 (0.33-0.83); p = 0.006). No association was seen for IGF-1 (adjusted HR 0.90 (0.55-1.45); p = 0.65). For the physically inactive, neither IGF-1 nor IGFBP-3 was associated with disease specific survival. CONCLUSIONS: This study supports the hypothesis that the beneficial effects of physical activity in reducing colorectal cancer mortality may occur through interactions with the insulin-like growth factor axis and in particular IGFBP-3.
BACKGROUND: Recent reports have shown that physical activity improves the outcome of patients with colorectal cancer as well as breast and prostate cancer. However, the mechanisms whereby physical activity reduces cancer mortality are not well established. METHODS: Incident cases of colorectal cancer were identified among participants of the Melbourne Collaborative Cohort Study, a prospective cohort study of 41,528 Australians recruited from 1990 to 1994. Information on tumour site and stage, treatments given, recurrences, and deaths were obtained from systematic review of the medical records. Baseline assessments of physical activity and body size were made, and cases with available plasma had pre-diagnosis insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) levels measured. We assessed associations between these hormones and colorectal cancer specific deaths with respect to physical activity. RESULTS: A total of 526 cases of colorectal cancer were identified, of which 443 had IGF-1/IGFBP-3 levels measured. Median follow up among survivors was 5.6 years. For the physically active, increasing IGFBP-3 by 26.2 nmol/l was associated with a 48% reduction in colorectal cancer specific deaths (adjusted hazard ratio (HR) 0.52 (0.33-0.83); p = 0.006). No association was seen for IGF-1 (adjusted HR 0.90 (0.55-1.45); p = 0.65). For the physically inactive, neither IGF-1 nor IGFBP-3 was associated with disease specific survival. CONCLUSIONS: This study supports the hypothesis that the beneficial effects of physical activity in reducing colorectal cancer mortality may occur through interactions with the insulin-like growth factor axis and in particular IGFBP-3.
Authors: R Roubenoff; R N Baumgartner; T B Harris; G E Dallal; M T Hannan; C D Economos; P M Stauber; P W Wilson; D P Kiel Journal: J Gerontol A Biol Sci Med Sci Date: 1997-05 Impact factor: 6.053
Authors: A C Williams; T J Collard; C M Perks; P Newcomb; M Moorghen; J M Holly; C Paraskeva Journal: Cancer Res Date: 2000-01-01 Impact factor: 12.701
Authors: J Ma; M N Pollak; E Giovannucci; J M Chan; Y Tao; C H Hennekens; M J Stampfer Journal: J Natl Cancer Inst Date: 1999-04-07 Impact factor: 13.506
Authors: Jeffrey A Meyerhardt; Denise Heseltine; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; James Thomas; Heidi Nelson; Renaud Whittom; Alexander Hantel; Richard L Schilsky; Charles S Fuchs Journal: J Clin Oncol Date: 2006-07-05 Impact factor: 44.544
Authors: Sheetal Hardikar; Polly A Newcomb; Peter T Campbell; Aung Ko Win; Noralane M Lindor; Daniel D Buchanan; Karen W Makar; Mark A Jenkins; John D Potter; Amanda I Phipps Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-14 Impact factor: 4.254
Authors: Jae Youn Chung; Dong Hoon Lee; Ji-Hye Park; Mi Kyung Lee; Dong-Woo Kang; Jihee Min; Dong-Il Kim; Duck Hyoun Jeong; Nam Kyu Kim; Jeffrey A Meyerhardt; Lee W Jones; Justin Y Jeon Journal: Support Care Cancer Date: 2013-01-06 Impact factor: 3.603
Authors: Dong Hoon Lee; Ji Young Kim; Mi Kyung Lee; Choae Lee; Ji-Hee Min; Duck Hyoun Jeong; Ji-Won Lee; Sang Hui Chu; Jeffrey A Meyerhardt; Jennifer Ligibel; Lee W Jones; Nam Kyu Kim; Justin Y Jeon Journal: Support Care Cancer Date: 2013-05-02 Impact factor: 3.603
Authors: Tao Fu; Emmanouil P Pappou; Angela A Guzzetta; Marilia de Freitas Calmon; Lifeng Sun; Alexander Herrera; Fan Li; Christopher L Wolfgang; Stephen B Baylin; Christine A Iacobuzio-Donahue; Weidong Tong; Nita Ahuja Journal: Ann Surg Date: 2016-02 Impact factor: 12.969
Authors: Charles S Fuchs; Richard M Goldberg; Daniel J Sargent; Jeffrey A Meyerhardt; Brian M Wolpin; Erin M Green; Henry C Pitot; Michael Pollak Journal: Clin Cancer Res Date: 2008-12-10 Impact factor: 12.531
Authors: David J Harriss; N Tim Cable; Keith George; Thomas Reilly; Andrew G Renehan; Najib Haboubi Journal: Sports Med Date: 2007 Impact factor: 11.136